Literature DB >> 19614710

Telomerase activity and telomere length in acute leukemia: correlations with disease progression, subtypes and overall survival.

Y Wang1, M Fang, X Sun, J Sun.   

Abstract

The progressive shortening of telomeres and the activation of telomerase are considered to be one of the important mechanisms in cellular immortalization and disease progression. Bone marrow samples were collected from 148 patients with acute leukemia (AL). Based on the stage of the disease, patients were divided into the newly diagnosed group, the relapsed group and the complete remission (CR) group. telomerase activity (TA) was examined by PCR-ELISA, and telomere length (TL) was examined by Southern blot analyses. TA and TL were analyzed in relation to AL stage and subtype. Five-year survival was analyzed using Kaplan-Meier survival curve. TA in AL patients was higher than healthy individuals. TA level was the highest in the relapsed group, followed by the newly diagnosed group, and then the CR group. TA had no difference between acute nonlymphocytic leukemia (ANLL) group and acute lymphocytic leukemia (ALL) group. But TA in group of subtype M3 was lower than other subtypes of ANLL. TL in AL group was shorter than the control group. TL was the shortest in the relapsed group, followed by the newly diagnosed group, and finally the CR group. TL exhibited an inverse correlation with TA. The group of patients with high TA had a significantly poorer five-year-survival than that of low TA group. TA is elevated and TL is shortened in AL patients. There is a significant inverse correlation between TL and TA. Patients in late-stage disease had shorter TL and higher TA than those in early stages. The shortened TL and elevated TA correlated with disease progression and relapse, and they may serve as prognostic factors for AL patients with poor outcome. M3 subtype is special with relative lower TA and long-lasting survival than other subtypes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19614710     DOI: 10.1111/j.1751-553X.2009.01178.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  6 in total

Review 1.  Telomere biology in hematopoiesis and stem cell transplantation.

Authors:  Shahinaz M Gadalla; Sharon A Savage
Journal:  Blood Rev       Date:  2011-07-20       Impact factor: 8.250

Review 2.  Biological and clinical implications of telomere dysfunction in myeloid malignancies.

Authors:  Ashwin Kishtagari; Justin Watts
Journal:  Ther Adv Hematol       Date:  2017-10-06

Review 3.  The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation.

Authors:  Limengmeng Wang; Haowen Xiao; Xing Zhang; Chong Wang; He Huang
Journal:  J Hematol Oncol       Date:  2014-08-20       Impact factor: 17.388

4.  Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome.

Authors:  Hee Sue Park; Jungeun Choi; Cha Ja See; Jung Ah Kim; Si Nae Park; Kyongok Im; Sung Min Kim; Dong Soon Lee; Sang Mee Hwang
Journal:  Ann Lab Med       Date:  2017-05       Impact factor: 3.464

Review 5.  Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies.

Authors:  Philipp Ernst; Florian H Heidel
Journal:  Cancers (Basel)       Date:  2021-02-04       Impact factor: 6.639

6.  Transcriptomic Analysis of Conserved Telomere Maintenance Component 1 (CTC1) and Its Association with Leukemia.

Authors:  Saadiya Zia; Netasha Khan; Komal Tehreem; Nazia Rehman; Rokayya Sami; Roua S Baty; Faris J Tayeb; Majed N Almashjary; Nouf H Alsubhi; Ghadeer I Alrefaei; Ramla Shahid
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.